Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoricoxib/Tramadol - Laboratorios Silanes

Drug Profile

Etoricoxib/Tramadol - Laboratorios Silanes

Alternative Names: E/T - Laboratorios Silanes; Tramadol/Etoricoxib - Laboratorios Silanes

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratorios Silanes
  • Class Anisoles; Cyclohexanols; Dimethylamines; Non-opioid analgesics; Opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Adrenergic uptake inhibitors; Cyclo-oxygenase 2 inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Pain(In volunteers, In adults) in Mexico (PO, Granules)
  • 14 Sep 2022 NCT05533073 - NP created; mailed the company to clarify the regulatory pathway for registration of the product; chem. str. req sent; indication assumed from the NCT record; as discussed, keep the NCT in HE though it is 90mg/50mg combination; reply awaited
  • 14 Sep 2022 Laboratorios Silanes completes a phase I trial in Pain in Mexico (NCT05533073)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top